Connect with us

Hi, what are you looking for?

Monday, Sep 26, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

The weed wire

FSD Pharma scales back cultivation, implements furlough

The cutback excludes staff working staggered shifts to ensure operations continuity and procedures necessary to maintain licensing

FSD Pharma scales back cultivation, implements furlough

As Ontario’s number of confirmed COVID-19 cases surpasses 500, FSD Pharma Inc. (NASDAQ: HUGE and CSE: HUGE.CN), is scaling back production at its subsidiary-owned production facility in the Town of Cobourg.

The pharmaceutical R&D company said Monday that the 25,000 square-foot facility, run by wholly owned subsidiary FV Pharma Inc., has began a systematic scale back of its cultivation operations in line with evolving guidance from provincial and federal health officials.

FSD said it has implemented a leave of absence policy for its workforce, which excludes certain staff working staggered shifts to ensure operations continuity and procedures necessary to maintain licensing.

Read more: COVID-19 pandemic puts Canadian cannabis operations in limbo

The company has also closed its facility to partners and ceased partner-related operations, according to a statement.

Following the declaration of a state of emergency by the Ontario government and the confirmation of infections in Cobourg, FSD CEO Raza Bokhari said his company has taken necessary steps to ensure the safety of its employees and town residents.

“The COVID-19 pandemic is rapidly shifting and we have assembled a working group within FSD Pharma to perpetually monitor the unprecedented market realities that are shaping the local and global business landscape,” he said. “We are putting forth our best efforts to make deliberate, definitive and difficult decisions to mitigate any present and future setbacks.”

Bokhari said his company is committed to persevering through these uncharted times and is prepared to adjust its strategy to adapt to the new normal that is emerging.

“We are confident that we are resiliently positioned to continue to advance our specialty pharmaceutical R&D efforts to target the  endocannabinoid system of the human body,” he said.

Under FSD’s other owned subsidiary, FSD BioSciences Inc., it conducts specialty biotech pharmaceutical research focused on developing  FDA-approved synthetic compounds targeting the endocannabinoid system. According to the company, it’s developing treatments for certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system.

Top photo by Cannabis Tours via Wikimedia Commons

 

nick@mugglehead.com

@nick_laba

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Canada

Study will evaluate psilocybin efficacy in healthcare workers with mental health challenges related to pandemic

COVID-19

Cue Health expects to push its new service out to patients who test positive on any COVID-19 test within the next few weeks.

News

The U.S. House of Representatives passed legislation on Thursday to subsidize the domestic semiconductor microchip industry in a bid to compete with the Chinese...

Business

The company sought protection as a result of declining revenue stemming from COVID-19 government mandates